This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Re, M. C. Articles by La Placa, M. Search for Related Content PubMed PubMed Citation Articles by Re, M. C. Articles by La Placa, M.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, 03 1996, 230-232, Vol 3, No. 2
Copyright © 1996 by the American Society for Microbiology. All rights reserved.

Antibody against human immunodeficiency virus type 1 (HIV-1) Tat protein may have influenced the progression of AIDS in HIV-1-infected hemophiliac patients

MC Re, G Furlini, M Vignoli, E Ramazzotti, G Zauli and M La Placa
Institute of Microbiology, University of Bologna, St. Orsola General Hospital, Italy.

Retrospective analysis of serum samples from a group of hemophiliac patients who became infected with human immunodeficiency virus type 1 (HIV-1) between 1984 and 1985 has shown that, at variance with other HIV-1-infected patients, at the onset, or at least at a very early phase of HIV-1 infection, they constantly have elevated levels of antibodies against HIV-1-transactivating Tat protein and an absent or barely detectable p24 antigenemia. Anti-Tat antibodies in initial serum samples from hemophiliac patients were probably the consequence of the passive administration of immunoglobulins present in low- or intermediate-purity clotting factor concentrates prepared from HIV-1- infected blood. Furthermore, the analysis of serial serum samples obtained during the course of the disease, in which passively acquired anti-Tat antibodies were substituted by actively produced antibodies, demonstrated an inverse relationship between anti-Tat antibody and p24 anti-genemia levels throughout the observation period. These data seem to suggest that anti-Tat antibody may have some influence on the course of HIV-1 infection.

This article has been cited by other articles:

• Agwale, S. M., Shata, M. T., Reitz, M. S. Jr., Kalyanaraman, V. S., Gallo, R. C., Popovic, M., Hone, D. M. (2002). A Tat subunit vaccine confers protective immunity against the immune-modulating activity of the human immunodeficiency virus type-1 Tat protein in mice. Proc. Natl. Acad. Sci. USA 99: 10037-10041 [Abstract] [Full Text]  
• Cohen, S. S., Li, C., Ding, L., Cao, Y., Pardee, A. B., Shevach, E. M., Cohen, D. I. (1999). Pronounced acute immunosuppression in vivo mediated by HIV Tat challenge. Proc. Natl. Acad. Sci. USA 96: 10842-10847 [Abstract] [Full Text]  
• Boykins, R. A., Mahieux, R., Shankavaram, U. T., Gho, Y. S., Lee, S. F., Hewlett, I. K., Wahl, L. M., Kleinman, H. K., Brady, J. N., Yamada, K. M., Dhawan, S. (1999). Cutting Edge: A Short Polypeptide Domain of HIV-1-Tat Protein Mediates Pathogenesis. J. Immunol. 163: 15-20 [Abstract] [Full Text]